flibanserin (Addyi): FDA status

Approved Approved Dec 15, 2025. Indication: hypoactive sexual desire disorder in postmenopausal women under 65. Company: Sprout Pharmaceuticals.

Regulatory history

All products in the FDA Tracker

Loading today's edition…